Related references
Note: Only part of the references are listed.Activity of OSE-2101 in HLA-A2+non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO): Final results of phase III Atalante-1 randomised trial
B. Besse et al.
ANNALS OF ONCOLOGY (2021)
Comparison of Bayesian and Frequentist Multiplicity Correction for Testing Mutually Exclusive Hypotheses Under Data Dependence
Sean Chang et al.
BAYESIAN ANALYSIS (2021)
Quantification of prior impact in terms of effective current sample size
Manuel Wiesenfarth et al.
BIOMETRICS (2020)
Seamless phase II/III/IIIb clinical trial designs with different endpoints for different phases
Hui Quan et al.
COMMUNICATIONS IN STATISTICS-THEORY AND METHODS (2020)
Advanced Utilization of Intermediate Endpoints for Making Optimized Cost-Effective Decisions in Seamless Phase II/III Oncology Trials
Linda Z. Sun et al.
STATISTICS IN BIOPHARMACEUTICAL RESEARCH (2020)
An adaptive power prior for sequential clinical trials - Application to bridging studies
Adrien Ollier et al.
STATISTICAL METHODS IN MEDICAL RESEARCH (2020)
Adaptive seamless clinical trials using early outcomes for treatment or subgroup selection: Methods, simulation model and their implementation in R
Tim Friede et al.
BIOMETRICAL JOURNAL (2020)
Predictively consistent prior effective sample sizes
Beat Neuenschwander et al.
BIOMETRICS (2020)
Clinical Trials Impacted by the COVID-19 Pandemic: Adaptive Designs to the Rescue?
Cornelia Ursula Kunz et al.
STATISTICS IN BIOPHARMACEUTICAL RESEARCH (2020)
A Bayesian non-inferiority approach using experts' margin elicitation application to the monitoring of safety events
Camille Aupiais et al.
BMC MEDICAL RESEARCH METHODOLOGY (2019)
Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols
Jay J. H. Park et al.
TRIALS (2019)
A hybrid phase I-II/III clinical trial design allowing dose re-optimization in phase III
Andrew G. Chapple et al.
BIOMETRICS (2019)
Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples
L. A. Renfro et al.
ANNALS OF ONCOLOGY (2017)
Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both
Janet Woodcock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Flexible selection of a single treatment incorporating short-term endpoint information in a phase II/III clinical trial
Nigel Stallard et al.
STATISTICS IN MEDICINE (2015)
The power prior: theory and applications
Joseph G. Ibrahim et al.
STATISTICS IN MEDICINE (2015)
A conditional error function approach for subgroup selection in adaptive clinical trials
T. Friede et al.
STATISTICS IN MEDICINE (2012)
Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods
Peter K. Kimani et al.
STATISTICS IN MEDICINE (2012)
Group-Sequential Methods for Adaptive Seamless Phase II/III Clinical Trials
Nigel Stallard
JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2011)
An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints
Martin Jenkins et al.
PHARMACEUTICAL STATISTICS (2011)
A confirmatory seamless phase II/III clinical trial design incorporating short-term endpoint information
Nigel Stallard
STATISTICS IN MEDICINE (2010)
Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology
Werner Brannath et al.
STATISTICS IN MEDICINE (2009)
Dose selection in seamless phase II/III clinical trials based on efficacy and safety
Peter K. Kimani et al.
STATISTICS IN MEDICINE (2009)
Determining the effective sample size of a parametric prior
Satoshi Morita et al.
BIOMETRICS (2008)
Mixtures of g priors for Bayesian variable selection
Feng Liang et al.
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION (2008)
Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint
Heinz Schmidli et al.
STATISTICS IN MEDICINE (2007)
Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim:: General concepts
Frank Bretz et al.
BIOMETRICAL JOURNAL (2006)
Adaptive seamless phase II/III designs - Background, operational aspects, and examples
Jeff Maca et al.
DRUG INFORMATION JOURNAL (2006)
Share Paper
